US2017319540A1
|
|
Methods and Compositions for the Treatment of Non-Alcoholic Steatohepatitis
|
AU2016308568A1
|
|
Pharmaceutical formulations
|
AU2016203698A1
|
|
Low Dose Topiramate/Phentermine Composition and Methods of Use Thereof
|
AU2016203699A1
|
|
Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity
|
AU2016262391A1
|
|
Compositions and methods for the treatment or prevention of pulmonary hypertension
|
MX2017009110A
|
|
Combination therapy for pulmonary hypertension.
|
CA2958110A1
|
|
Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
|
CA2949094A1
|
|
Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use
|
EP3142644A1
|
|
Orally administrable formulations for the controlled release of a pharmacologically active agent
|
AU2014331995A1
|
|
Methods of preventing progression to type 2 diabetes mellitus
|
AU2014213552A1
|
|
Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
|
AU2014202143A1
|
|
Low Dose Topiramate / Phentermine Composition and Methods of Use Thereof
|
AU2014202124A1
|
|
Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity
|
US2014294950A1
|
|
Methods of treating obesity in responder and non-responder populations
|
US2014288944A1
|
|
Methods of regulating access to qsymia to mitigate potential drug-associated risks
|
AU2013201500A1
|
|
Novel combinations comprising a phosphodiesterase-5 inhibitor and their use
|
AU2012201640A1
|
|
Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
|
US2011224196A1
|
|
Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent
|
CA2776971A1
|
|
Treatment with cholinergic agonists
|
US2010087402A1
|
|
Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
|